Literature DB >> 2316772

Prevalence of markers for hepatitis B and hepatitis D in a municipal house of correction.

M A Barry1, D Gleavy, K Herd, P J Schwingl, B G Werner.   

Abstract

Following an outbreak of hepatitis B (HBV) in a municipal house of correction, HBV markers were detected in 173/406 (43 percent) inmates and 10/129 (8 percent) staff. Of the 173 HBV-infected inmates, 14 (8 percent) had hepatitis D (HDV) markers compared to 0/10 staff members. Intravenous drugs use (IVDU) was most strongly associated with HBV marker presence. Increasing duration of imprisonment, history of hepatitis B and especially IVDU were associated with the prevalence of HDV markers.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2316772      PMCID： PMC1404596          DOI： 10.2105/ajph.80.4.471

Source DB:  PubMed          Journal:  Am J Public Health        ISSN： 0090-0036            Impact factor:   9.308


  11 in total

1.  Estimability and estimation in case-referent studies.

Authors:  O Miettinen
Journal:  Am J Epidemiol       Date:  1976-02       Impact factor: 4.897

2.  The delta agent.

Authors:  M Rizzetto
Journal:  Hepatology       Date:  1983 Sep-Oct       Impact factor: 17.425

3.  Hepatitis B markers among Michigan prisoners.

Authors:  M L Kaufman; K L Faiver; J K Harness
Journal:  Ann Intern Med       Date:  1983-04       Impact factor: 25.391

4.  Prevalence of hepatitis B surface antigen and antibody at a state prison in Kansas.

Authors:  J P Koplan; J A Walker; J A Bryan; K R Berquist
Journal:  J Infect Dis       Date:  1978-04       Impact factor: 5.226

5.  Incidence of hepatitis B in the penitentiary of New Mexico.

Authors:  H F Hull; L H Lyons; J M Mann; S C Hadler; R Steece; M R Skeels
Journal:  Am J Public Health       Date:  1985-10       Impact factor: 9.308

6.  Epidemiology and clinical impact of hepatitis D virus (delta) infection.

Authors:  I M Jacobson; J L Dienstag; B G Werner; D B Brettler; P H Levine; I K Mushahwar
Journal:  Hepatology       Date:  1985 Mar-Apr       Impact factor: 17.425

7.  Hepatitis B virus infection in prisons. A seroepidemiological survey in prisoners and attending staff.

Authors:  M Chiaramonte; R Trivello; G Renzulli; L Zampieri; A Fanecco; A Floreani; R Naccarato
Journal:  J Hyg (Lond)       Date:  1982-08

8.  Hepatitis B markers in United States drug addicts with special emphasis on the delta hepatitis virus.

Authors:  A Ponzetto; L B Seeff; Z Buskell-Bales; K G Ishak; J H Hoofnagle; H J Zimmerman; R H Purcell; J L Gerin
Journal:  Hepatology       Date:  1984 Nov-Dec       Impact factor: 17.425

9.  Hepatitis B virus-associated coinfection and superinfection with delta agent: indistinguishable disease with different outcome.

Authors:  F Caredda; E Rossi; A d'Arminio Monforte; L Zampini; T Re; B Meroni; M Moroni
Journal:  J Infect Dis       Date:  1985-05       Impact factor: 5.226

10.  Hepatitis B in Wisconsin male prisoners: considerations for serologic screening and vaccination.

Authors:  R F Anda; S B Perlman; D J D'Alessio; J P Davis; V N Dodson
Journal:  Am J Public Health       Date:  1985-10       Impact factor: 9.308
View more
  3 in total

1.  Ongoing transmission of hepatitis B virus infection among inmates at a state correctional facility.

Authors:  Amy J Khan; Edgar P Simard; William A Bower; Heather L Wurtzel; Marina Khristova; Karla D Wagner; Kathryn E Arnold; Omana V Nainan; Madeleine LaMarre; Beth P Bell
Journal:  Am J Public Health       Date:  2005-10       Impact factor: 9.308

2.  Sources of heterogeneity in hepatitis B virus (HBV) seroprevalence estimates from U.S. adult incarcerated populations: A systematic review and meta-regression analysis.

Authors:  Amy J Harzke; Karen J Goodman; Patricia D Mullen; Jacques Baillargeon
Journal:  Int J Prison Health       Date:  2010-06

3.  Heterogeneity in hepatitis B virus (HBV) seroprevalence estimates from U.S. adult incarcerated populations.

Authors:  Amy J Harzke; Karen J Goodman; Patricia D Mullen; Jacques Baillargeon
Journal:  Ann Epidemiol       Date:  2009-07-12       Impact factor: 3.797
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.